Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations

被引：202

作者：

Pal, Sumanta K. ^{[1
]}

Rosenberg, Jonathan E. ^{[2
]}

Hoffman-Censits, Jean H. ^{[3
]}

Berger, Raanan ^{[4
]}

Quinn, David I. ^{[5
]}

Galsky, Matthew D. ^{[6
]}

Wolf, Juergen ^{[7
]}

Dittrich, Christian ^{[8
]}

Keam, Bhumsuk ^{[9
]}

Delord, Jean-Pierre ^{[10
]}

Schellens, Jan H. M. ^{[11
]}

Gravis, Gwenaelle ^{[12
]}

Medioni, Jacques ^{[13
]}

Maroto, Pablo ^{[14
]}

Sriuranpong, Virote ^{[15
,16
]}

Charoentum, Chaiyut ^{[17
]}

Burris, Howard A. ^{[18
]}

Grunwald, Viktor ^{[19
]}

Petrylak, Daniel ^{[20
]}

Vaishampayan, Ulka ^{[21
]}

Gez, Eliahu ^{[22
]}

De Giorgi, Ugo ^{[23
]}

Lee, Jae-Lyun ^{[24
]}

Voortman, Jens ^{[25
]}

Gupta, Sumati ^{[26
]}

Sharma, Sunil ^{[26
]}

Mortazavi, Amir ^{[27
]}

Vaughn, David J. ^{[28
]}

Isaacs, Randi ^{[29
]}

Parker, Katie ^{[29
]}

Chen, Xueying ^{[29
]}

Yu, Kun ^{[30
]}

Porter, Dale ^{[30
]}

Porta, Diana Graus ^{[31
]}

Bajorin, Dean F. ^{[2
]}

机构：

[1] City Hope Natl Med Ctr, Duarte, CA USA

[2] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10065 USA

[3] Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Philadelphia, PA 19107 USA

[4] Chaim Sheba Med Ctr, Ramat Gan, Israel

[5] USC Norris Canc Ctr, Los Angeles, CA USA

[6] Mt Sinai Hosp, New York, NY 10029 USA

[7] Univ Hosp Cologne, Ctr Integrated Oncol, Cologne, Germany

[8] Kaiser Franz Josef Spital, ACR ITR VIEnna, Appl Canc Res Inst Translat Res Vienna, Vienna, Austria

[9] Seoul Natl Univ Hosp, Seoul, South Korea

[10] IUCT Oncopole, Toulouse, France

[11] Netherlands Canc Inst, Amsterdam, Netherlands

[12] Inst Paoli Calmettes, Marseilles, France

[13] Hop Europeen Georges Pompidou, Paris, France

[14] Hosp Santa Creu & Sant Pau, Barcelona, Spain

[15] Chulalongkorn Univ, Fac Med, Bangkok, Thailand

[16] King Chulalongkorn Mem Hosp, Bangkok, Thailand

[17] Maharaj Nakorn Chiangmai Hosp, Chiang Mai, Thailand

[18] Sarah Cannon Res Inst, Nashville, TN USA

[19] Clin Hematol Hemostasis Oncol & Stem Cell Transp, Med Sch Hannover, Hannover, Germany

[20] Yale Sch Med, New Haven, CT USA

[21] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA

[22] Tel Aviv Sourasky Med Ctr Ichilov, Tel Aviv, Israel

[23] Inst Sci Romagnolo Studio & Cura Tumori IRST IRC, Meldola, Italy

[24] Univ Ulsan, Asan Med Ctr, Coll Med, Seoul, South Korea

[25] Vrije Univ Amsterdam Med Ctr, Canc Ctr Amsterdam, Amsterdam, Netherlands

[26] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA

[27] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA

[28] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA

[29] Novartis Pharmaceut, E Hanover, NJ USA

[30] Novartis Inst BioMed Res, Cambridge, MA USA

[31] Novartis Pharma AG, Basel, Switzerland

来源：

CANCER DISCOVERY | 2018年 / 8卷 / 07期

关键词：

CISPLATIN-INELIGIBLE PATIENTS; ACQUIRED-RESISTANCE; GENETIC ALTERATIONS; BLADDER-CANCER; SINGLE-ARM; MULTICENTER; PEMBROLIZUMAB; NVP-BGJ398; MUTATIONS;

D O I：

10.1158/2159-8290.CD-18-0229

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

BGJ398, a potent and selective pan-FGFR antagonist, was prospectively evaluated in patients with metastatic urothelial carcinoma bearing a diverse array of FGFR3 alterations. Patients (N = 67) who were unable to receive platinum chemotherapy were enrolled. The majority (70.1%) had received two or more prior antineoplastic therapies. BGJ398 was administered orally at 125 mg/day on a 3 weeks on, 1 week off schedule until unacceptable toxicity or progression. The primary endpoint was the response rate. Among 87 patients treated, an overall response rate of 25.4% was observed and an additional 38.8% of patients had disease stabilization, translating to a disease control rate of 64.2%. The most common treatment-emergent toxicities were hyperphosphatemia, elevated creatinine, fatigue, constipation, and decreased appetite. Further examination of BGJ398 in this disease setting is warranted. SIGNIFICANCE: BJG398 is active in patients with alterations in FGFR3, resulting in both reductions in tumor volume and stabilization of disease. (C) 2018 AACR.

引用

页码：812 / 821

页数：10

共 50 条

[41] GENOMIC ORGANIZATION OF THE MOUSE FIBROBLAST-GROWTH-FACTOR-RECEPTOR-3 (FGFR3) GENE
PEREZCASTRO, AV
WILSON, J
ALTHERR, MR
GENOMICS, 1995, 30 (02) : 157 - 162
[42] Fibroblast growth factor receptor 3 (FGFR3) expression in non-Hodgkin lymphoma
Larson, A.
Cook, J. R.
LABORATORY INVESTIGATION, 2007, 87 : 249A - 250A
[43] Genomic organization of the human fibroblast growth factor receptor 3 (FGFR3) gene and comparative sequence analysis with the mouse fgfr3 gene
PerezCastro, AV
Wilson, J
Altherr, MR
GENOMICS, 1997, 41 (01) : 10 - 16
[44] A phase III study of INCB054828 as adjuvant therapy in patients (pts) with high-risk urothelial carcinoma (UC) harboring fibroblast growth factor receptor 3 (FGFR3) genomic alterations
Necchi, A.
Perez-Gracia, J. L.
Loriot, Y.
Witjes, W.
Montorsi, F.
Bjartell, A.
Shariat, S. F.
ANNALS OF ONCOLOGY, 2018, 29
[45] Efficacy of futibatinib, an irreversible fibroblast growth factor receptor (FGFR) inhibitor, in breast cancer models with FGFR alterations
Saridogan, Turcin
Akcakanat, Argun
Zhao, Ming
Evans, Kurt W.
Yuca, Erkan
Scott, Stephen
Kirby, Bryce P.
Zheng, Xiaofeng
Damodaran, Senthil
Meric-Bernstam, Funda
CANCER RESEARCH, 2022, 82 (04)
[46] Final results from a phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma harboring an FGFR2 gene fusion or rearrangement.
Javle, Milind M.
Roychowdhury, Sameek
Kelley, Robin Kate
Sadeghi, Saeed
Macarulla, Teresa
Waldschmidt, Dirk Thomas
Goyal, Lipika
Borbath, Ivan
El-Khoueiry, Anthony B.
Yong, Wei-Peng
Philip, Philip Agop
Bitzer, Michael
Tanasanvimon, Suebpong
Li Ai
Pande, Amit
Shepherd, Stacie Peacock
Moran, Susan
Abou-Alfa, Ghassan K.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
[47] A phase 1 study of LY3076226, a fibroblast growth factor receptor 3 (FGFR3) antibody–drug conjugate, in patients with advanced or metastatic cancer
Christian Kollmannsberger
Carolyn D. Britten
Anthony J. Olszanski
Joan Andrews Walker
Wei Zang
Melinda D. Willard
David B. Radtke
Daphne L. Farrington
Katherine M. Bell-McGuinn
Amita Patnaik
Investigational New Drugs, 2021, 39 : 1613 - 1623
[48] Identification of Fibroblast Growth Factor Receptor 3 (FGFR3) as a Protein Receptor for Botulinum Neurotoxin Serotype A (BoNT/A)
Jacky, Birgitte P. S.
Garay, Patton E.
Dupuy, Jerome
Nelson, Jeremy B.
Cai, Brian
Molina, Yanira
Wang, Joanne
Steward, Lance E.
Broide, Ron S.
Francis, Joseph
Aoki, K. Roger
Stevens, Raymond C.
Fernandez-Salas, Ester
PLOS PATHOGENS, 2013, 9 (05)
[49] Efficacy of TAS-120, an irreversible fibroblast growth factor receptor inhibitor (FGFRi), in patients with cholangiocarcinoma and FGFR pathway alterations previously treated with chemotherapy and other FGFRi's
Tran, B.
Meric-Bernstam, F.
Arkenau, H-T.
Bahleda, R.
Kelley, R. K.
Hierro, C.
Ahn, D.
Zhu, A.
Javle, M.
Winkler, R.
He, H.
Huang, J.
Goyal, L.
ANNALS OF ONCOLOGY, 2018, 29
[50] Marker lesion study of oral FGFR inhibitor BGJ398 in patients with FGFR3-altered intermediate-risk nonmuscle-invasive bladder cancer
Cha, Eugene K.
Iyer, Gopa
Funt, Samuel Aaron
Regazzi, Ashley Marie
Francis, Jasmine
Heinemann, M. H.
Ostrovnaya, Irina
Dalbagni, Guido
Bajorin, Dean F.
Bochner, Bernard H.
Rosenberg, Jonathan E.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)

← 1 2 3 4 5 →